Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Shares lifted to record highs by lockdown easing, benign Fed

Thu, 08th Apr 2021 10:52

* Europe's STOXX index up 0.3%

* S&P futures reach another peak, Nikkei lags

* Asian stock markets : https://tmsnrt.rs/2zpUAr4

* Fed sticking to stimulus, Powell set to speak

* Treasury yields dip, leaving dollar aimless

By Huw Jones

LONDON, April 8 (Reuters) - Stocks in Europe reached record
highs on Thursday, buoyed by optimism in Britain over easing
lockdown restrictions, while a benign outlook for U.S. interest
rates was set to push Wall Street to new heights.

The European STOXX index of leading 600 companies
rose 0.3%, hitting a new high of 436.66 points. London's blue
chip FTSE 100 index was up 0.2%.

"It's looking good as evaluations in Europe are much lower
than they are in the U.S. so there is potentially more upside.
The line of least resistance for European markets is higher,"
said Michael Hewson, chief market analyst at CMC Markets.

"In terms of economic re-opening, there is enough optimism
built in at the moment to drive markets quite a bit higher from
here, and the Fed has reiterated it's going to remain on hold
for a while," Hewson said.

Minutes of the Federal Reserve's last policy meeting,
published on Wednesday, showed members felt the economy was
still far short of target and were in no rush to scale back
their $120 billion a month of bond buying.

Fed Chairman Jerome Powell speaks at an International
Monetary Fund event later on Thursday and is likely to reiterate
the dovish outlook.

The European Central Bank was due to publish accounts for
its March 11 policy meeting amid debate about when it should
start tapering its pandemic stimulus, with the euro area
recovery still in doubt.

Wall Street was also set to reach fresh peaks on Thursday
with e-mini futures on the S&P 500 rising 0.25% after
rising to a record high, and Nasdaq futures up 0.7%

Gains by U.S. Treasuries also helped, although
analysts said markets will be tested next week when the U.S.
earnings seasons gets underway.

In Asia, MSCI's broadest index of Asia-Pacific shares
outside Japan inched up 0.3% in quiet trade.
Japan's Nikkei slipped 0.3%, not helped by news Tokyo's
governor had asked for emergency measures to stem a surge of
COVID-19 infections.

Yields on 10-year Treasuries have eased back
to 1.669% from the recent 14-month high of 1.776%, but have
struggled to break under 1.59%.

The decline coincided with a dip in the dollar index to
92.360 from its recent five-month high at 93.439.

The euro was steady at $1.1871, after rising as high
as $1.1914 overnight following a surprisingly upbeat survey of
European Union business activity.

In commodity markets, gold was at $1,743 an ounce
after meeting resistance around $1,745.

Oil prices fell after official figures showed a big
increase in U.S. gasoline stockpiles, causing concerns about
demand for crude weakening in the world's biggest consumer of
the resource at a time when supplies around the world are
rising.

Brent fell 22 cents to $62.94 a barrel. U.S. crude
lost 37 cents to $59.40 per barrel.

(Aditional reporting by Wayne Cole and Chibuike Oguh; editing
by Larry King)

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.